Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the efficacy of atomoxetine (ATX) treatment for the
mild to moderate cognitive disturbances frequently experienced by women during the menopause
transition. In addition, we seek to determine, using the Brown Attention Deficit Disorder
Scale (BADDS), whether and to what degree peri- and early post-menopausal women experience
cognitive disturbances which overlap with the impairments of executive function
characteristic of adults with attention deficit disorder (ADHD).